GSTM5

Across TCGA pan-cancer cohorts, GSTM5 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of GSTM5’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where GSTM5 RNA is repressed in tumor relative to normal tissue. In most cancer types GSTM5 is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

BLCA, LUAD, and THCA are the cancer types where GSTM5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GSTM5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−3.415	<.001	11	view →
LUAD	Female	III,IV	−1.954	<.001	11	view →
THCA	Female	II,III,IV	−1.917	<.001	11	view →
COAD	All	IV	−1.655	<.001	11	view →
KIRC	Male	II,III,IV	−1.000	<.001	11	view →
KICH	Female	II,III,IV	−1.557	<.001	10	view →
LUSC	Female	II,III,IV	−2.362	<.001	9	view →
KIRP	Male	All	−1.054	<.001	9	view →
UCEC	All	II,III,IV	−3.944	<.001	8	view →
STAD	Female	All	−2.011	<.001	8	view →
HNSC	Male	All	−0.714	<.001	8	view →
BRCA	All	II,III,IV	−2.426	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

GSTM5–BLCA

Open the BLCA breakdown →